Positive data for Roche multiple sclerosis injection
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Subscribe To Our Newsletter & Stay Updated